Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Histiocytic Sarcoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

tusamitamab ravtansine 2Ramucirumab 2Gemcitabine 2Docetaxel 2pembrolizumab 1necitumumab 1Paclitaxel 1LY3023414 1Erlotinib Hydrochloride 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Non-small Cell Lung Cancer Metastatic × LY3023414 × Clear all
NCT02443337 2020-12-09

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Eli Lilly and Company

Phase 2 Terminated
31 enrolled 14 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡